Hercules Capital Provides $25MM Credit Facility to Locus Biosciences
Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.
October 20, 2021
Bryan Jadot | Hercules Capital | Locus Biosciences | Paul Garofolo
Ian Koplin